FDA Commissioner Margaret Hamburg, MD, testified at a House Energy and Commerce subcommittee hearing on last year’s fungal meningitis outbreak due to contaminated products from a compounding pharmacy. To date, the tainted drugs have caused 51 deaths and sickened more than 730 people, according to Dr. Hamburg’s testimony.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Dr. Hamburg presented a risk-based framework for improving the safety of compounded drugs. Under the framework, the FDA would categorize compounding practices as either traditional — such as combining ingredients to develop a prescribed and medically necessary medication — or non-traditional, such as compounding that is for a medical need but poses higher risks.
Oversight of traditional compounding would be the purview of state regulation, whereas non-traditional compounding would have to meet federal standards, according to the testimony.
More Articles on Sterile Compounding:
Health Groups Recommend 5 Ways to Make Sterile Compounding Safer
Survey: 11% of Pharmacists Reported Contamination of High-Risk Compounded Sterile Products in Past Year
Institute for Safe Medication Practices Issues Guidelines on Sterile Compounding
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.